Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 4/2012

01.08.2012 | Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Etiologies of Intracerebral Hematomas

verfasst von: Qingliang T. Wang, Stanley Tuhrim

Erschienen in: Current Atherosclerosis Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Intracerebral hemorrhage (ICH) remains a life-threatening disease that carries significant morbidity and mortality despite recent diagnostic and management advances. Various conditions are associated with increased risk of intracerebral hemorrhage. Understanding the etiology of these conditions and their pathophysiological contribution to ICH will likely lead to better therapeutic and preventative measures and improve the morbidity and mortality associated with intracerebral hemorrhage. We will review the current literature regarding important etiologies/risk factors of intracerebral hemorrhage.
Literatur
1.
Qureshi AI, et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450–60.PubMedCrossRef
2.
Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus thrombosis. J Neurol. 2004;251(1):11–23.PubMedCrossRef
3.
Sayama CM, et al. Capillary telangiectasias: clinical, radiographic, and histopathological features. Clinical article. J Neurosurg. 2010;113(4):709–14.PubMedCrossRef
4.
Tang SC, et al. Diffuse capillary telangiectasia of the brain manifested as a slowly progressive course. Cerebrovasc Dis. 2003;15(1–2):140–2.PubMedCrossRef
5.
6.
van Asch CJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–76.PubMedCrossRef
7.
Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40(4):1082–90.PubMedCrossRef
8.
Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373(9675):1632–44.PubMedCrossRef
9.
Lee WC, et al. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis. 2007;23(1):57–65.PubMedCrossRef
10.
Taylor TN, et al. Lifetime cost of stroke in the United States. Stroke. 1996;27(9):1459–66.PubMedCrossRef
11.
Ariesen MJ, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060–5.PubMedCrossRef
12.
13.
Zia E, et al. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke. 2007;38(10):2681–5.PubMedCrossRef
14.
Bogucki J, et al. A new CT-based classification of spontaneous supratentorial intracerebral haematomas. Neurol Neurochir Pol. 2009;43(3):236–44.PubMed
15.
16.
Qureshi AI, et al. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke: a 20-year follow-up of the national health and nutrition survey. Stroke. 2002;33(12):2781–8.PubMedCrossRef
17.
Woo D, et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke. 2004;35(7):1703–8.PubMedCrossRef
18.
Qureshi AI, et al. Intracranial atherosclerotic disease: an update. Ann Neurol. 2009;66(6):730–8.PubMedCrossRef
19.
Vernooij MW, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam scan study. Neurology. 2008;70(14):1208–14.PubMedCrossRef
20.
• Poels MM et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke. 2010;41(10 Suppl):S103-6.PubMedCrossRef
21.
Quinones-Hinojosa A, et al. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus. 2003;15(4):E3.PubMedCrossRef
22.
Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35(2):99–103.PubMedCrossRef
23.
Fisher CM. Hypertensive cerebral hemorrhage. Demonstration of the source of bleeding. J Neuropathol Exp Neurol. 2003;62(1):104–7.PubMed
24.
Rosenblum WI. Fibrinoid necrosis of small brain arteries and arterioles and miliary aneurysms as causes of hypertensive hemorrhage: a critical reappraisal. Acta Neuropathol. 2008;116(4):361–9.PubMedCrossRef
25.
Challa VR, Moody DM, Bell MA. The Charcot-Bouchard aneurysm controversy: impact of a new histologic technique. J Neuropathol Exp Neurol. 1992;51(3):264–71.PubMedCrossRef
26.
Panerai RB. Cerebral autoregulation: from models to clinical applications. Cardiovasc Eng. 2008;8(1):42–59.PubMedCrossRef
27.
Noorani A, Sadat U, Gaunt ME. Cerebral hemodynamic changes following carotid endarterectomy: 'cerebral hyperperfusion syndrome'. Expert Rev Neurother. 2010;10(2):217–23.PubMedCrossRef
28.
Ogasawara K, et al. Intracranial hemorrhage associated with cerebral hyperperfusion syndrome following carotid endarterectomy and carotid artery stenting: retrospective review of 4494 patients. J Neurosurg. 2007;107(6):1130–6.PubMedCrossRef
29.
Dunatov S, Antoncic I, Bralic M. Hemodynamic changes in the posterior cerebral circulation triggered by insufficient sympathetic innervation–cause of primary intracerebral hemorrhage? Med Hypotheses. 2011;76(5):668–9.PubMedCrossRef
30.
Hefzy HM, et al. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR Am J Neuroradiol. 2009;30(7):1371–9.PubMedCrossRef
31.
Kang CK, et al. Hypertension correlates with lenticulostriate arteries visualized by 7T magnetic resonance angiography. Hypertension. 2009;54(5):1050–6.PubMedCrossRef
32.
• Arima H et al. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial. Stroke. 2011;42(8):2339–41.PubMedCrossRef
33.
Broderick J, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38(6):2001–23.PubMedCrossRef
34.
• Mayer SA et al. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension registry. Crit Care Med. 2011;39(10):2330–6.PubMedCrossRef
35.
Ohwaki K, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35(6):1364–7.PubMedCrossRef
36.
Qureshi AI, Palesch YY. Antihypertensive treatment of acute cerebral hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011;15(3):559–76.PubMedCrossRef
37.
• Qureshi AI et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010;67(5):570–6.PubMedCrossRef
38.
• Anderson CS et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke. 2010;41(2):307–12.PubMedCrossRef
39.
Smeda JS, Daneshtalab N. The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. J Cereb Blood Flow Metab. 2011;31(2):476–85.PubMedCrossRef
40.
• Witmer C et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2011;152(2):211–6.PubMedCrossRef
41.
Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140(4):378–84.PubMedCrossRef
42.
Nuss R, Soucie JM, Evatt B. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol. 2001;68(1):37–42.PubMedCrossRef
43.
del Zoppo GJ, Mori E. Hematologic causes of intracerebral hemorrhage and their treatment. Neurosurg Clin N Am. 1992;3(3):637–58.PubMed
44.
Gronbaek H, et al. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case–control study. BMC Gastroenterol. 2008;8:16.PubMedCrossRef
45.
Miyasaka M, et al. Vitamin K deficiency bleeding with intracranial hemorrhage: focus on secondary form. Emerg Radiol. 2007;14(5):323–9.PubMedCrossRef
46.
Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin. 2003;21(1):167–92.PubMedCrossRef
47.
Psaila B, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009;114(23):4777–83.PubMedCrossRef
48.
•• Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010;30(5):565–72.PubMedCrossRef
49.
• Sonneville R et al. Neurologic complications and outcomes of infective endocarditis in critically ill patients: the ENDOcardite en REAnimation prospective multicenter study. Crit Care Med. 2011;39(6):1474–81.PubMedCrossRef
50.
Kannoth S, et al. Intracranial infectious aneurysm: presentation, management and outcome. J Neurol Sci. 2007;256(1–2):3–9.PubMedCrossRef
51.
• van Beijnum J et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306(18):2011–9.PubMedCrossRef
52.
Laakso A, et al. Risk of hemorrhage in patients with untreated Spetzler-Martin grade IV and V arteriovenous malformations: a long-term follow-up study in 63 patients. Neurosurgery. 2011;68(2):372–7. discussion 378.PubMedCrossRef
53.
• Mohr JP et al. The ARUBA trial: current status, future hopes. Stroke. 2010;41(8):e537-40.PubMedCrossRef
54.
Hoffman C, et al. Associated aneurysms in pediatric arteriovenous malformations and the implications for treatment. Neurosurgery. 2011;69(2):315–22.PubMedCrossRef
55.
Hernesniemi JA, et al. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008;63(5):823–9. discussion 829–31.PubMedCrossRef
56.
• Washington CW, McCoy KE, Zipfel GJ. Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. Neurosurg Focus. 2010;29(3):E7.PubMedCrossRef
57.
Ruiz DS, Yilmaz H, Gailloud P. Cerebral developmental venous anomalies: current concepts. Ann Neurol. 2009;66(3):271–83.PubMedCrossRef
58.
•• Vasileyko V et al. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann NY Acad Sci. 2010;1207:58–70.CrossRef
59.
Jellinger KA, Lauda F, Attems J. Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage. Eur J Neurol. 2007;14(8):923–8.PubMedCrossRef
60.
Ritter MA, et al. Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology. 2005;64(7):1233–7.PubMedCrossRef
61.
Smith EE, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke. 2010;41(9):1933–8.PubMedCrossRef
62.
Potsi S, et al. Superficial cortical siderosis. Acta Neurol Belg. 2011;111(2):162.PubMed
63.
Touze E, et al. Fibromuscular dysplasia of cervical and intracranial arteries. Int J Stroke. 2010;5(4):296–305.PubMedCrossRef
64.
Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. 1997;99 Suppl 2:S238–40.PubMed
65.
Iwama T, et al. Mechanism of intracranial rebleeding in moyamoya disease. Clin Neurol Neurosurg. 1997;99 Suppl 2:S187–90.PubMedCrossRef
66.
Saeki N, et al. Hemorrhagic type moyamoya disease. Clin Neurol Neurosurg. 1997;99 Suppl 2:S196–201.PubMed
67.
Ceri M et al. Massive intracerebral hemorrhage associated with Wegener granulomatosis. Rheumatol Int. 2011.
68.
Ishikawa K, Matsuura S. Occlusive thromboaortopathy (Takayasu's disease) and pregnancy. Clinical course and management of 33 pregnancies and deliveries. Am J Cardiol. 1982;50(6):1293–300.PubMedCrossRef
69.
Katz JM, Segal AZ. Incidence and etiology of cerebrovascular disease in patients with malignancy. Curr Atheroscler Rep. 2005;7(4):280–8.PubMedCrossRef
70.
Licata B, Turazzi S. Bleeding cerebral neoplasms with symptomatic hematoma. J Neurosurg Sci. 2003;47(4):201–10. discussion 210.PubMed
71.
Turgut M, et al. Pituitary apoplexy: an overview of 186 cases published during the last century. Acta Neurochir (Wien). 2010;152(5):749–61.CrossRef
72.
de San Pedro JR, et al. Massive hemorrhage in hemangioblastomas Literature review. Neurosurg Rev. 2010;33(1):11–26.PubMedCrossRef
73.
Cheng MH, Lin JW. Intracranial meningioma with intratumoral hemorrhage. J Formos Med Assoc. 1997;96(2):116–20.PubMed
74.
Wong PF, et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 2011;11:CD001272.PubMed
75.
•• Geeganage CM et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012.
76.
Valgimigli M, Minarelli M. Triple antiplatelet therapy in acute coronary syndromes. Drugs. 2011;71(13):1703–19.PubMedCrossRef
77.
Foerch C, et al. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006;37(8):2165–7.PubMedCrossRef
78.
• Moussouttas M et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocrit Care. 2010;12(1):24–9.PubMedCrossRef
79.
•• Hansen ML et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41.PubMedCrossRef
80.
Qureshi AI, et al. Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States. Cardiovasc Drugs Ther. 2005;19(5):371–3.PubMedCrossRef
81.
Zubkov AY, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008;65(10):1320–5.PubMedCrossRef
82.
Cucchiara B, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39(11):2993–6.PubMedCrossRef
83.
Davis SM, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175–81.PubMedCrossRef
84.
Mayer SA, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37.PubMedCrossRef
85.
Flaherty ML, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5(3):197–201.PubMedCrossRef
86.
Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26(8):1471–7.PubMedCrossRef
87.
Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRef
88.
•• Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012;33(3):199–208.PubMedCrossRef
89.
Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.PubMedCrossRef
90.
Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.PubMedCrossRef
91.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.
92.
Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008;79(10):1093–9.PubMedCrossRef
93.
Diedler J, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41(2):288–94.PubMedCrossRef
94.
• Goldstein JN et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol. 2010;67(8):965–9.PubMedCrossRef
95.
Morgan T, et al. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–51.PubMedCrossRef
96.
Morgan T, et al. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217–20.PubMedCrossRef
97.
Ngo QN, et al. External ventricular drains in pediatric patients. Pediatr Crit Care Med. 2009;10(3):346–51.PubMedCrossRef
98.
Bouras T, Sgouros S. Complications of endoscopic third ventriculostomy. J Neurosurg Pediatr. 2011;7(6):643–9.PubMedCrossRef
99.
Misaki K, et al. Intracerebral hemorrhage secondary to ventriculoperitoneal shunt insertion–four case reports. Neurol Med Chir (Tokyo). 2010;50(1):76–9.CrossRef
100.
Kimmelman J, et al. Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord. 2011;26(8):1415–21.PubMedCrossRef
101.
Seijo FJ, et al. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochir (Wien). 2007;149(9):867–75. discussion 876.CrossRef
102.
Gooch MR, et al. Complications of cranioplasty following decompressive craniectomy: analysis of 62 cases. Neurosurg Focus. 2009;26(6):E9.PubMedCrossRef
103.
• Toossi S et al. Neurovascular complications of cocaine use at a tertiary stroke center. J Stroke Cerebrovasc Dis. 2010;19(4):273–8.PubMedCrossRef
104.
Pozzi M, Roccatagliata D, Sterzi R. Drug abuse and intracranial hemorrhage. Neurol Sci. 2008;29 Suppl 2:S269–70.PubMedCrossRef
105.
• Martin-Schild S et al. Intracerebral hemorrhage in cocaine users. Stroke. 2010;41(4):680–4. PubMedCrossRef
106.
Pedersen HS, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet. 1999;353(9155):812–3.PubMedCrossRef
107.
• Westover MB et al. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. 2011;68(5):573–9.PubMedCrossRef
108.
Goldstein LB, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70(24 Pt 2):2364–70.PubMedCrossRef
109.
• Hackam DG, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011;124(20):2233–42.PubMedCrossRef
110.
Bang OY, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68(10):737–42.PubMedCrossRef
111.
• Rodriguez-Luna D, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. Stroke. 2011;42(9):2447–52.PubMedCrossRef
112.
Bateman BT, et al. Intracerebral hemorrhage in pregnancy: frequency, risk factors, and outcome. Neurology. 2006;67(3):424–9.PubMedCrossRef
113.
Rayes M, et al. Good outcome in HELLP syndrome with lobar cerebral hematomas. Neurocrit Care. 2011;14(2):276–80.PubMedCrossRef
114.
Caprio F, Bernstein RA. Duration of anticoagulation after cerebral venous sinus thrombosis. Neurocrit Care. 2011.
Metadaten
Titel
Etiologies of Intracerebral Hematomas
verfasst von
Qingliang T. Wang
Stanley Tuhrim
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 4/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0253-0

Weitere Artikel der Ausgabe 4/2012

Current Atherosclerosis Reports 4/2012 Zur Ausgabe

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Medical Versus Surgical Management of Intracerebral Hematomas

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Clinical Syndromes and Management of Intracerebral Hemorrhage

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Management of Hemorrhage from Cavernous Malformations

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

The Pathophysiology and Clinical Presentation of Cerebral Amyloid Angiopathy

Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Management of Ruptured Brain Arteriovenous Malformations

Genetics (AJ Marian, Section Editor)

The Enigma of Genetics Etiology of Atherosclerosis in the Post-GWAS Era

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise